[go: up one dir, main page]

NI201800008A - Inhibidores peptídicos del receptor de interleucina 23 y su uso para tratar enfermedades inflamatorias - Google Patents

Inhibidores peptídicos del receptor de interleucina 23 y su uso para tratar enfermedades inflamatorias

Info

Publication number
NI201800008A
NI201800008A NI201800008A NI201800008A NI201800008A NI 201800008 A NI201800008 A NI 201800008A NI 201800008 A NI201800008 A NI 201800008A NI 201800008 A NI201800008 A NI 201800008A NI 201800008 A NI201800008 A NI 201800008A
Authority
NI
Nicaragua
Prior art keywords
interleukin
receptor
inflammatory diseases
treat inflammatory
peptidic inhibitors
Prior art date
Application number
NI201800008A
Other languages
English (en)
Inventor
Bhandari Ashok
Bourne Gregory
Cheng Xiaoli
Troy Frederick Brian
Zhang Jie
V Patel Dinesh
Liu David
Original Assignee
Protagonist Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2015/040658 external-priority patent/WO2016011208A1/en
Application filed by Protagonist Therapeutics Inc filed Critical Protagonist Therapeutics Inc
Publication of NI201800008A publication Critical patent/NI201800008A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención proporciona inhibidores peptídicos novedosos del receptor de interleucina 23 y composiciones y métodos relacionados para utilizar estos inhibidores peptídicos para el tratamiento o la prevención de diversas enfermedades y trastornos, incluidas enfermedades intestinales inflamatorias.
NI201800008A 2015-07-15 2018-01-11 Inhibidores peptídicos del receptor de interleucina 23 y su uso para tratar enfermedades inflamatorias NI201800008A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/US2015/040658 WO2016011208A1 (en) 2014-07-17 2015-07-15 Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
US14/800,627 US9624268B2 (en) 2014-07-17 2015-07-15 Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
US201562264820P 2015-12-08 2015-12-08
US201662281123P 2016-01-20 2016-01-20
PCT/US2016/042680 WO2017011820A2 (en) 2015-07-15 2016-07-15 Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases

Publications (1)

Publication Number Publication Date
NI201800008A true NI201800008A (es) 2018-06-29

Family

ID=57757647

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201800008A NI201800008A (es) 2015-07-15 2018-01-11 Inhibidores peptídicos del receptor de interleucina 23 y su uso para tratar enfermedades inflamatorias

Country Status (23)

Country Link
EP (1) EP3341011A4 (es)
JP (1) JP6858174B2 (es)
KR (1) KR102513978B1 (es)
CN (1) CN108348580B (es)
AU (1) AU2016293619B2 (es)
BR (1) BR112018000691A2 (es)
CA (1) CA2991984A1 (es)
CL (3) CL2018000128A1 (es)
CO (1) CO2018000349A2 (es)
CR (1) CR20180029A (es)
DO (1) DOP2018000010A (es)
EA (1) EA035733B9 (es)
EC (1) ECSP18002929A (es)
HK (1) HK1257747A1 (es)
IL (1) IL256827A (es)
MX (1) MX384213B (es)
NI (1) NI201800008A (es)
PE (1) PE20180571A1 (es)
PH (1) PH12018500086A1 (es)
SG (1) SG10201912066SA (es)
SV (1) SV2018005614A (es)
UA (1) UA123772C2 (es)
WO (1) WO2017011820A2 (es)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107652289B (zh) 2012-06-13 2020-07-21 因塞特控股公司 作为fgfr抑制剂的取代的三环化合物
CN105451755B (zh) 2013-03-15 2020-10-13 领导医疗有限公司 铁调素类似物和其用途
JP6449244B2 (ja) 2013-04-19 2019-01-09 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｆｇｆｒ抑制剤としての二環式複素環
EP3960754A3 (en) 2014-05-16 2022-07-06 Protagonist Therapeutics, Inc. Alpha4beta7 integrin thioether peptide antagonists
EP4378536A3 (en) 2014-07-17 2024-10-09 Protagonist Therapeutics, Inc. Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
WO2016054445A1 (en) 2014-10-01 2016-04-07 Protagonist Therapeutics, Inc. Novel cyclic monomer and dimer peptides having integrin antagonist activity
EP3200812B8 (en) 2014-10-01 2021-04-28 Protagonist Therapeutics, Inc. Novel alpha4beta7 peptide monomer and dimer antagonists
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
ES2751669T3 (es) 2015-02-20 2020-04-01 Incyte Corp Heterociclos bicíclicos como inhibidores FGFR
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
US10787490B2 (en) 2015-07-15 2020-09-29 Protaganist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
GB2545898B (en) 2015-12-21 2019-10-09 Sutura Therapeutics Ltd Improved drug delivery by conjugating oligonucleotides to stitched/stapled peptides
CA3009834A1 (en) 2015-12-30 2017-07-06 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
EP3432906A4 (en) 2016-03-23 2020-04-01 Protagonist Therapeutics, Inc. METHOD FOR SYNTHETIZING ALPHA4BETA7 PEPTIDE ANTAGONISTS
JP2020505352A (ja) * 2017-01-18 2020-02-20 プロタゴニスト セラピューティクス， インコーポレイテッド インターロイキン−２３受容体のペプチド阻害剤および炎症性疾患を治療するためのそれらの使用
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
GB2563875B (en) * 2017-06-28 2020-08-19 Sutura Therapeutics Ltd Improvements in drug delivery
CA3073806A1 (en) 2017-09-11 2019-03-14 Protagonist Therapeutics, Inc. Opioid agonist peptides and uses thereof
WO2019157268A1 (en) 2018-02-08 2019-08-15 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
PE20210919A1 (es) 2018-05-04 2021-05-19 Incyte Corp Sales de un inhibidor de fgfr
CN119241541A (zh) 2018-05-04 2025-01-03 因赛特公司 Fgfr抑制剂的固体形式和其制备方法
CA3104418A1 (en) * 2018-07-12 2020-01-16 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
CN110015978B (zh) * 2019-04-29 2021-03-19 康化（上海）新药研发有限公司 O-[2-[[叔丁氧羰基]氨基]乙基]-n-[芴甲氧羰基]-l-酪氨酸的合成方法
BR112021026815A2 (pt) * 2019-07-01 2022-06-07 Valitor Inc Ligantes hidrofílicos para conjugados de peptídeo multivalentes
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CN116082455A (zh) 2019-07-10 2023-05-09 领导医疗有限公司 白细胞介素-23受体的肽抑制剂及其用于治疗炎症性疾病的用途
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
GEP20247679B (en) 2019-10-14 2024-10-10 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
EP3819307A1 (en) * 2019-11-07 2021-05-12 CytoKi Pharma ApS Therapeutic derivatives of interleukin-22
CA3163875A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
IL293001A (en) 2019-12-04 2022-07-01 Incyte Corp Derivatives of fgfr repressors
US12018057B2 (en) 2020-01-15 2024-06-25 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
RS66991B1 (sr) * 2020-01-15 2025-08-29 Janssen Biotech Inc Peptidni inhibitori interleukin-23 receptora i njihova primena u lečenju inflamatornih bolesti
BR112022026700A2 (pt) * 2020-06-29 2023-01-24 Univ Washington Polipeptídeos de ligação de receptor de il23 humano
EP4211468A4 (en) 2020-09-11 2024-10-09 Glympse Bio, Inc. DETECTION OF EX VIVO PROTEASE ACTIVITY FOR DETECTION/DIAGNOSTIC, STAGING, MONITORING AND TREATMENT OF DISEASES
KR20230110570A (ko) * 2020-11-20 2023-07-24 얀센 파마슈티카 엔.브이. 인터류킨-23 수용체의 펩티드 억제제의 조성물
JP2023145581A (ja) * 2020-11-20 2023-10-11 ヤンセン ファーマシューティカ エヌ．ベー． インターロイキン－２３受容体のペプチド阻害剤の組成物
JP2024513575A (ja) 2021-04-12 2024-03-26 インサイト・コーポレイション Ｆｇｆｒ阻害剤及びネクチン－４標的化剤を含む併用療法
AR126101A1 (es) 2021-06-09 2023-09-13 Incyte Corp Heterociclos tricíclicos como inhibidores de fgfr
WO2022261160A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
UY39857A (es) 2021-07-14 2023-02-28 Janssen Biotech Inc Inhibidores peptídicos lipidados del receptor de interleucina-23
WO2023288017A2 (en) * 2021-07-14 2023-01-19 Janssen Biotech, Inc. Bicyclic peptide inhibitors of interleukin-23 receptor
TW202332683A (zh) * 2021-07-14 2023-08-16 美商健生生物科技公司 介白素－２３受體之肽抑制劑
KR20240111800A (ko) 2021-12-01 2024-07-17 질랜드 파마 에이/에스 인터루킨-23 수용체의 펩티드 억제제
US20250223627A1 (en) * 2022-03-09 2025-07-10 Glympse Bio, Inc. Fluorogenic substrates for aminopeptidase detection in biofluids
CN114751962B (zh) * 2022-03-17 2023-11-07 北京大学 订书肽、其制备方法及其制药用途
JP2025521647A (ja) 2022-06-30 2025-07-10 サノフイ 選択的ｉｌ－２３受容体アンタゴニストとしての新規ペプチド
CN120435485A (zh) * 2022-11-21 2025-08-05 詹森药业有限公司 环状肽的合成
CN121127485A (zh) * 2023-01-16 2025-12-12 詹森药业有限公司 白介素-23受体的多环肽抑制剂
WO2024155547A2 (en) * 2023-01-16 2024-07-25 Janssen Pharmaceutica Nv Peptide inhibitors of interleukin-23 receptor
CN120659801A (zh) 2023-01-31 2025-09-16 詹森药业有限公司 用于制备白介素-23受体的结晶肽抑制剂的方法
KR20260007614A (ko) * 2023-05-04 2026-01-14 시젱 하이스코 파마수티칼 씨오., 엘티디. 인터루킨-23 수용체의 펩타이드 억제제의 제조 및 이의 용도
EP4471048A1 (en) 2023-06-01 2024-12-04 Zealand Pharma A/S Peptide inhibitors of interleukin-23 receptor
EP4471049A1 (en) 2023-06-01 2024-12-04 Zealand Pharma A/S Peptide inhibitors of interleukin-23 receptor
WO2025051920A1 (en) 2023-09-08 2025-03-13 Sanofi New peptides as selective il-23 receptor inhibitors
WO2025051912A1 (en) 2023-09-08 2025-03-13 Sanofi New peptides as selective il-23 receptor inhibitors
WO2026013260A1 (en) 2024-07-12 2026-01-15 Zealand Pharma A/S Peptide inhibitors of interleukin-23 receptor

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5942492A (en) * 1996-11-12 1999-08-24 Angstrom Pharmaceuticals, Inc. Cyclic peptides that bind to urokinase-type plasminogen activator receptor
MX2009008241A (es) 2007-02-15 2009-10-08 Univ Indiana Res & Tech Corp Co-agonistas de receptor de glucagon/glp-1.
WO2009007849A2 (en) * 2007-07-06 2009-01-15 Valorisation Hsj, Societe En Commandite Il-23 receptor antagonists and uses thereof
CA2707840A1 (en) 2007-08-20 2009-02-26 Allozyne, Inc. Amino acid substituted molecules
US10416172B2 (en) * 2010-03-31 2019-09-17 Medical Diagnostic Laboratories, Llc Recombinant soluble truncated IL-23 receptor (IL-23R) capable of inhibiting IL-23R-mediated cell signaling
US8946150B2 (en) 2011-06-14 2015-02-03 Medical Diagnostic Laboratories, LLC. Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof
US9169292B2 (en) * 2011-06-14 2015-10-27 Medical Diagnostic Laboratories, Llc Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof
AU2014331812B2 (en) * 2013-10-09 2019-01-17 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for downregulation of pro-inflammatory cytokines
EP4378536A3 (en) * 2014-07-17 2024-10-09 Protagonist Therapeutics, Inc. Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases

Also Published As

Publication number Publication date
WO2017011820A2 (en) 2017-01-19
CN108348580A (zh) 2018-07-31
PH12018500086A1 (en) 2018-07-30
JP2018522008A (ja) 2018-08-09
EA035733B9 (ru) 2021-01-14
DOP2018000010A (es) 2018-03-30
KR102513978B1 (ko) 2023-03-27
HK1257747A1 (zh) 2019-10-25
KR20180030663A (ko) 2018-03-23
EP3341011A4 (en) 2019-02-20
CL2018000128A1 (es) 2018-06-15
AU2016293619A1 (en) 2018-02-01
JP6858174B2 (ja) 2021-04-14
EA035733B1 (ru) 2020-07-31
CL2021000343A1 (es) 2021-08-06
BR112018000691A2 (pt) 2018-09-18
EA201890325A1 (ru) 2018-06-29
CN108348580B (zh) 2022-05-10
AU2016293619B2 (en) 2021-02-25
IL256827A (en) 2018-03-29
HK1259149A1 (zh) 2019-11-29
WO2017011820A3 (en) 2017-02-23
CR20180029A (es) 2018-06-05
EP3341011A2 (en) 2018-07-04
CO2018000349A2 (es) 2018-07-10
UA123772C2 (uk) 2021-06-02
PE20180571A1 (es) 2018-04-04
CL2018003322A1 (es) 2019-01-18
CA2991984A1 (en) 2017-01-19
ECSP18002929A (es) 2018-03-31
MX384213B (es) 2025-03-14
MX2018000542A (es) 2018-06-27
SG10201912066SA (en) 2020-02-27
SV2018005614A (es) 2018-05-22

Similar Documents

Publication Publication Date Title
ECSP18002929A (es) Inhibidores peptídicos del receptor de interleucina 23 y su uso para tratar enfermedades inflamatorias
AR119389A1 (es) Inhibidores de péptidos del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias
CY1122344T1 (el) Blautia stercosis και wexlerae για χρηση στην θεραπευτικη αγωγη φλεγμονωδων και αυτοανοσων νοσων
BR112022000328A2 (pt) Inibidores peptídicos do receptor de interleucina-23 e seu uso para tratar doenças inflamatórias
EP4378536A3 (en) Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
MX2020001774A (es) Composiciones y métodos para tratar enfermedad colestásica.
GT201600233A (es) Compuestos y composiciones como agonistas del receptor tipo toll 7
EA201891199A1 (ru) Композиции, содержащие бактериальные штаммы
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA201890047A1 (ru) Композиции, содержащие бактериальные штаммы
EA201692529A1 (ru) Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
EA201792047A1 (ru) Новые соединения
MX388562B (es) Composiciones y métodos para el tratamiento de trastornos de almacenamiento lisosomal y trastornos caracterizados por disfunción lisosomal.
UY37038A (es) Composiciones y métodos para disminuir la expresión de tau
EA201792604A1 (ru) Ингибиторы аутотаксина и их применения
MX2019001634A (es) Compuestos amidas, composiciones farmacéuticas de estos y métodos para utilizarlos.
EA201791937A1 (ru) Противовоспалительные полипептиды
CL2016002321A1 (es) Compuestos derivados del ácido 2-8-5-cloropirimidin-2-ilamino-6,7,8,9-tetrahidro-5h-pirido3,2-bindol-5-ilacético, moduladores del receptor de prostaglandina d2 composición farmacéutica y su uso para el tratamiento de enfermedadestrastornos alérgicosinmunitarios.
EA202091524A1 (ru) Ингибиторы рецептора, активируемого протеазой 2
MX393805B (es) Peptidos modificados para uso en el tratamiento de trastornos neurodegenerativos.
MX383460B (es) Derivados peptidicos novedosos y sus usos.
PH12017501694A1 (en) Compositions for the treatment of fibrosis and fibrosis-related diseases
MX2019001183A (es) Composiciones para el tratamiento de fibrosis pulmonar.
DOP2017000136A (es) Compuestos para tratar el cáncer